USnews.com recently discussed what they believe to be “10 of the best healthcare stocks to buy for 2020”.
Among what you would already guess to be on their list they discussed;
DaVita (NYSE: DVA) – A Denver-based company with a network of nearly 2,700 outpatient dialysis centers.
Swiss drug maker Norvatis (NYSE: NVS) is a global pharma powerhouse. A recent agreement to acquire The Medicines Co. for $9.7 billion gives Novartis a potential blockbuster cardiovascular drug
It’s remarkable more people don’t marvel at Japan’s Takeda Pharmaceutical, (NYSE: TAK) which has been around since 1781, and has no trouble keeping pace with the modern markets after levering up for a megadeal to acquire biotech company Shire for $62 billion in 2018.
CVS Health (NYSE: CVS) also made the list. Which coincidently, is a retailer along with Walmart (NYSE: WMT), and Amazon.com (NASDAQ: AMZN) for a product made by a company that can do very well on its own for the remainder of 2020.
More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).
Take a look at Glucose Health, Inc. (OTC Pink: GLUC). Trading with less than a $20 million valuation, Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®.
The company’s flagship product GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain glucose (blood sugar) levels in a normal healthy range.
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetic nutrition/medical foods space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.